SAGE Therapeutics Announces Closing Of Initial Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts, which includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock. All of the common stock was offered by SAGE. The company's common stock is listed on The NASDAQ Global Market under the symbol "SAGE."

Help employers find you! Check out all the jobs and post your resume.